Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
As the federal government ends pre-approved benefits during the early stages of the COVID-19 pandemic, low-income Americans could receive less food assistance or lose their eligibility altogether.
Read Full Newsargenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.
Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.
The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.
A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.
Personalized Care Improvements Identified for Older Patients with Skin Cancer
New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc
What to Expect at the 2026 Maui Derm Conference
1.
Decoding calcifications in breast cancer: Towards personalized medicine
2.
A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.
3.
Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US
4.
Radioactive ion beams successfully treat animal tumors in study
5.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
1.
Navigating the Complexities of Melanoma Staging: A Comprehensive Guide
2.
Unlocking the Potential of Leukemia Treatment: A New Hope for Patients
3.
Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation
4.
Decoding the Future: Cancer Genomics and Radiomics in Oncology
5.
Colon cancer: Risk factors, warning signs and treatment options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
2.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
4.
Navigating the Complexities of Ph Negative ALL - Part IV
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge